The role of topical immune response modifiers in skin cancer

被引：29

作者：

Woodmansee, Courtney ^{[1
]}

Pillow, Jessica ^{[1
]}

Skinner, Robert B., Jr. ^{[1
]}

机构：

[1] Univ Tennessee, Dept Med, Div Dermatol, Memphis, TN 38104 USA

来源：

DRUGS | 2006年 / 66卷 / 13期

关键词：

D O I：

10.2165/00003495-200666130-00001

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Topical immune response modifiers include imiquimod and resiquimod. The mechanism of action of immune response modifiers is complex and not completely understood. It involves the stimulation of innate and cell-mediated immune responses through Toll-like receptor-mediated induction of cytokines. Imiquimod is approved for the treatment of actinic keratoses, superficial basal cell carcinomas and warts; it has also been documented to successfully treat other forms of skin cancer such as squamous cell carcinoma in situ, melanoma and extramammary Paget's disease.

引用

页码：1657 / 1664

页数：8

共 35 条

[1]

*3M PHARM, 2005, ALD IM CREAM 5

[2] Imiquimod: a novel treatment for lentigo maligna [J].

Ahmed, I ;

Berth-Jones, J .

BRITISH JOURNAL OF DERMATOLOGY, 2000, 143 (04) :843-845

[3] Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle [J].

Berman, B ;

Sullivan, T ;

De Araujo, T ;

Nadji, M .

BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 :59-61

[4]

Berman B, 2005, CANC SKIN, P499

[5] Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream [J].

Beutner, KR ;

Geisse, JK ;

Helman, D ;

Fox, TL ;

Ginkel, A ;

Owens, ML .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1999, 41 (06) :1002-1007

[6]

DELROSSO JQ, 2003, SKIN AGING, V11, P44

[7] Treatment of melanoma in situ on sun-damaged skin with topical 5% imiquimod cream complicated by the development of invasive disease [J].

Fisher, GH ;

Lang, PG .

ARCHIVES OF DERMATOLOGY, 2003, 139 (07) :945-947

[8] Immunotherapy of basal cell carcinoma: Evolving approaches [J].

Gaspari, AA ;

Sauder, DN .

DERMATOLOGIC SURGERY, 2003, 29 (10) :1027-1034

[9] Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: A double-blind, randomized, vehicle-controlled study [J].

Geisse, JK ;

Rich, P ;

Pandya, A ;

Gross, K ;

Andres, K ;

Ginkel, A ;

Owens, M .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (03) :390-398

[10] Topical immunomodulation in dermatology: Potential of Toll-like receptor agonists [J].

Hengge, UR ;

Ruzicka, T .

DERMATOLOGIC SURGERY, 2004, 30 (08) :1101-1112

← 1 2 3 4 →